Tokyo, Aug. 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058699) titled 'Integrative Analysis of Circulating Tumor DNA and Digital Pathology Score for Postoperative Risk Assessment in Colorectal Cancer' on Aug. 5.
Study Type:
Observational
Primary Sponsor:
Institute - National Cancer Center Hospital East
Condition:
Condition - Malignant solid tumors
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To evaluate the prognostic and lymph node metastasis prediction performance of the combination of blood circulating tumor DNA (ctDNA) status and digital pathology score using deep learning in colorectal cancer patients who have undergone radical surgical treatment (including radical surgical treatment after local resection).
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Colorectal cancer patients undergoing radical surgical treatment enrolled in the MONSTAR-SCREEN-3 study (cohort B) who have not withdrawn consent or refused secondary use of their samples and information.
Key exclusion criteria - Data required for this study are missing.
Cases for which the principal investigator determines that enrollment in this study is inappropriate.
Target Size - 200
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 04 Month 20 Day
Date of IRB - 2025 Year 06 Month 05 Day
Anticipated trial start date - 2025 Year 06 Month 09 Day
Last follow-up date - 2029 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067113
Disclaimer: Curated by HT Syndication.
